Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.

<h4>Background</h4>Hepatitis C genotype 6 (HCV-6) is prevalent in Southeast Asia. Data on the efficacy of direct-acting antiviral agents in chronic HCV-6 patients is limited and pegylated interferon (Peg-IFN) plus ribavirin (RBV) combination therapy remains standard therapy for those pat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiwei Wang, Fen Liu, Fang Wei, Hong Ren, Huaidong Hu
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0f000d0d03364f1e8955ec1c1b4764ee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0f000d0d03364f1e8955ec1c1b4764ee
record_format	dspace
spelling	oai:doaj.org-article:0f000d0d03364f1e8955ec1c1b4764ee2021-11-11T08:21:41ZEfficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.1932-620310.1371/journal.pone.0100128https://doaj.org/article/0f000d0d03364f1e8955ec1c1b4764ee2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24963667/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Hepatitis C genotype 6 (HCV-6) is prevalent in Southeast Asia. Data on the efficacy of direct-acting antiviral agents in chronic HCV-6 patients is limited and pegylated interferon (Peg-IFN) plus ribavirin (RBV) combination therapy remains standard therapy for those patients.<h4>Aim</h4>Meta-analysis was performed to assess the efficacy and safety of Peg-IFN plus RBV combination therapy for chronic HCV-6 patients.<h4>Methods</h4>Relevant studies were found by database search through Medline, Embase, Web of Science and The Cochrane Library. All published clinical trials assessing the efficacy of Peg-IFN plus RBV combination therapy for chronic HCV-6 patients were included. Sustained virological response rate (SVR) was pooled. We performed additional meta-analyses to compare the SVR outcomes of 24 versus 48 weeks of treatment in four head-to-head trials. Another second meta-analysis was also conducted to compare the efficacy of combination Peg-IFN plus RBV therapy in HCV-6 versus HCV-1 patients.<h4>Results</h4>Thirteen studies met the inclusion criteria. The pooled SVR of all single arms was 75% (95% CI: 0.68-0.81). The SVR of 24 weeks treatment was significantly lower than that at 48 weeks, with a risk difference of -14% (95% CI: -0.25 to -0.02, p = 0.02). However, when restricted to the patients with rapid virological response (RVR), there was no significant effect on SVR between these two treatment groups, with a risk difference of -1% (95% CI: -0.1 to 0.07, p = 0.67). The SVR in HCV-6 patients was significantly higher than that in HCV-1 patients, with a relative risk of 1.35 (95% CI: 1.16-1.57, p<0.001). Side effects were common, but rarely caused treatment discontinuation.<h4>Conclusions</h4>The results of this meta-analysis suggest that Peg-IFN plus RBV is effective and safe for HCV-6 patients. Shortening treatment seems to be feasible in HCV-6 patients with RVR when tolerance to treatment is poor. However, this decision should be made cautiously.Xiwei WangFen LiuFang WeiHong RenHuaidong HuPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 6, p e100128 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xiwei Wang Fen Liu Fang Wei Hong Ren Huaidong Hu Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.
description	<h4>Background</h4>Hepatitis C genotype 6 (HCV-6) is prevalent in Southeast Asia. Data on the efficacy of direct-acting antiviral agents in chronic HCV-6 patients is limited and pegylated interferon (Peg-IFN) plus ribavirin (RBV) combination therapy remains standard therapy for those patients.<h4>Aim</h4>Meta-analysis was performed to assess the efficacy and safety of Peg-IFN plus RBV combination therapy for chronic HCV-6 patients.<h4>Methods</h4>Relevant studies were found by database search through Medline, Embase, Web of Science and The Cochrane Library. All published clinical trials assessing the efficacy of Peg-IFN plus RBV combination therapy for chronic HCV-6 patients were included. Sustained virological response rate (SVR) was pooled. We performed additional meta-analyses to compare the SVR outcomes of 24 versus 48 weeks of treatment in four head-to-head trials. Another second meta-analysis was also conducted to compare the efficacy of combination Peg-IFN plus RBV therapy in HCV-6 versus HCV-1 patients.<h4>Results</h4>Thirteen studies met the inclusion criteria. The pooled SVR of all single arms was 75% (95% CI: 0.68-0.81). The SVR of 24 weeks treatment was significantly lower than that at 48 weeks, with a risk difference of -14% (95% CI: -0.25 to -0.02, p = 0.02). However, when restricted to the patients with rapid virological response (RVR), there was no significant effect on SVR between these two treatment groups, with a risk difference of -1% (95% CI: -0.1 to 0.07, p = 0.67). The SVR in HCV-6 patients was significantly higher than that in HCV-1 patients, with a relative risk of 1.35 (95% CI: 1.16-1.57, p<0.001). Side effects were common, but rarely caused treatment discontinuation.<h4>Conclusions</h4>The results of this meta-analysis suggest that Peg-IFN plus RBV is effective and safe for HCV-6 patients. Shortening treatment seems to be feasible in HCV-6 patients with RVR when tolerance to treatment is poor. However, this decision should be made cautiously.
format	article
author	Xiwei Wang Fen Liu Fang Wei Hong Ren Huaidong Hu
author_facet	Xiwei Wang Fen Liu Fang Wei Hong Ren Huaidong Hu
author_sort	Xiwei Wang
title	Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.
title_short	Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.
title_full	Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.
title_fullStr	Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.
title_full_unstemmed	Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.
title_sort	efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis c genotype 6: a meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/0f000d0d03364f1e8955ec1c1b4764ee
work_keys_str_mv	AT xiweiwang efficacyandsafetyofpegylatedinterferonplusribavirintherapyforchronichepatitiscgenotype6ametaanalysis AT fenliu efficacyandsafetyofpegylatedinterferonplusribavirintherapyforchronichepatitiscgenotype6ametaanalysis AT fangwei efficacyandsafetyofpegylatedinterferonplusribavirintherapyforchronichepatitiscgenotype6ametaanalysis AT hongren efficacyandsafetyofpegylatedinterferonplusribavirintherapyforchronichepatitiscgenotype6ametaanalysis AT huaidonghu efficacyandsafetyofpegylatedinterferonplusribavirintherapyforchronichepatitiscgenotype6ametaanalysis
_version_	1718439283870662656

Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.

Ejemplares similares